ESR1 and invasive breast carcinoma: We present the development and analytical validation of a highly sensitive and specific NAPA assay for the detection of four ESR1 mutations (Y537S, Y537C, Y537N and D538G) and its preliminary application in FFPE tumour tissues, CTCs, and paired plasma ctDNA of ER+ BrCa patients.